Paper Details

  1. Home
  2. Paper Details

An open label trial of anakinra to prevent respiratory failure in COVID-19.

Author: AkinosoglouKarolina, AvgoustouChristina, ChalvatzisStamatios, ChatzisLoukas, ChatzisStamatios, DalekosGeorge N, DareiotiMaria, Eugen-OlsenJesper, GatselisNikolaos, GeorgiadouSarah, Giamarellos-BourboulisEvangelos J, GkavogianniTheologia, GravvaniAreti, KarakikeEleni, KatriniKonstantina, KosmidouMaria, KyprianouMiltiades, KyriazopoulouEvdoxia, LoliGeorgia, LygouraVassiliki, MarantosTheodoros, MetallidisSymeon, MilionisHaralampos, MyrodiaDimitra-Melia, NeteaMihai G, PanagopoulosPeriklis, PapanikolaouIlias C, PetrakisVasileios, PoulakouGaryphallia, PrasianakiDanai, SaridakiMaria, StamouAliki, StefosAggelos, SyrigosKonstantinos, TrontzasIoannis P, TsachouridouOlga, TsiakosKonstantinos, VechlidisNikolaos, van der MeerJos Wm

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Early suPAR-guided anakinra treatment reduced severe respiratory failure (SRF) and restored the pro-/anti-inflammatory balance in patients with COVID-19. The treatment was associated with a decrease in inflammatory mediators and a lower risk of 30-day mortality.
Paper Details　
Original Abstract of the Article :
BACKGROUND: It was studied if early suPAR-guided anakinra treatment can prevent severe respiratory failure (SRF) of COVID-19. METHODS: A total of 130 patients with suPAR ≥6 ng/ml were assigned to subcutaneous anakinra 100 mg once daily for 10 days. Primary outcome was SRF incidence by day 14 define...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034977/

データ提供：米国国立医学図書館（NLM）

Anakinra: A Potential Oasis in the COVID-19 Storm

The COVID-19 pandemic has swept across the globe like a desert storm, leaving a trail of devastation in its wake. This research examines the potential of anakinra, an interleukin-1 receptor antagonist, as a preventative treatment for severe respiratory failure (SRF) in COVID-19 patients. The study, conducted with a large sample of patients, utilizes a suPAR-guided approach, focusing on a specific biomarker to identify individuals at high risk of SRF. The results show a significant reduction in SRF incidence and 30-day mortality in patients who received anakinra, suggesting its potential as a crucial tool in mitigating the severity of COVID-19.

A Beacon of Hope in the Storm: Anakinra's Impact

Anakinra's ability to reduce SRF incidence and mortality in COVID-19 patients is a significant finding. It signifies a potential breakthrough in treating this devastating disease, particularly in the context of the ongoing pandemic. These results are encouraging, offering a glimpse of hope in the face of this global health crisis. It's like finding a hidden spring in the midst of a sandstorm, offering respite and potential for survival.

Navigating the Storm: A Reminder of the Importance of Early Intervention

This study highlights the importance of early intervention in managing COVID-19 and preventing severe complications. Anakinra, when administered early in the course of illness, could potentially change the trajectory of the disease, providing a crucial buffer against the devastating effects of SRF. It serves as a reminder that proactive and timely action are paramount in combating this disease and preserving human life.

Dr. Camel's Conclusion

This research opens a new chapter in the fight against COVID-19, offering a potential therapeutic solution to prevent severe complications. Anakinra's ability to restore the pro-/anti-inflammatory balance and reduce SRF incidence is a significant discovery. It signifies a potential turning point in the battle against this devastating disease, offering a glimmer of hope in the midst of the storm.

Date :
  1. Date Completed 2021-04-14
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

33682678

DOI: Digital Object Identifier

PMC8034977

Related Literature

Article Analysis
・Side Effects of anakinra
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.